Hints and tips:
...“It’s been very disappointing because M&A’s always a huge catalyst for our sector,” said Brad Loncar, a biotech investor....
...“It has been the only BTK on the market until recently,” said Brad Loncar, founder of the Loncar Cancer Immunotherapy Index....
...the Loncar Cancer Immunotherapy exchange-traded fund, which holds shares in Juno....
International Edition